Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in hela cells-Reference-Cited by-同舟云学术

Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in hela cells

Published:2014-11 Issue:6 Volume:102 Page:444-455
ISSN:0006-3525
Container-title:Biopolymers
language:en
Short-container-title:Biopolymers

Author:

Qian Wen-Jian¹,Park Jung-Eun²,Lim Dan³,Lai Christopher C.¹,Kelley James A.¹,Park Suk-Youl⁴,Lee Ki Won⁴⁵,Yaffe Michael B.³,Lee Kyung S.²,Burke Terrence R.¹

Affiliation:

1. Chemical Biology Laboratory; Center for Cancer Research, National Institutes of Health; NCI at Frederick Frederick MD 21702

2. Laboratory of Metabolism; Center for Cancer Research, National Cancer Institute, National Institutes of Health; Bethesda MD 20892

3. Department of Biology and Biological Engineering; Center for Cancer Research, Massachusetts Institute of Technology; Cambridge MA 02139

4. Advanced Institutes of Convergence Technology, Seoul National University; Suwon 443-270 Republic of Korea

5. World Class University Biomodulation Major and Department of Agricultural Biotechnology; Seoul National University; Seoul 151-742 Republic of Korea

Funder

National Cancer Institute

National Institutes of Health

Publisher

Wiley

Subject

Organic Chemistry,Biomaterials,Biochemistry,General Medicine,Biophysics

Reference54 articles.

1. Polo-like kinases and the orchestration of cell division

2. Polo-like kinases, an introduction

3. Structure and function of Polo-like kinases

4. Polo-Like Kinases: A Team in Control of the Division

5. Polo-like kinases: conservation and divergence in their functions and regulation

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Specific inhibition of an anticancer target, polo-like kinase 1, by allosterically dismantling its mechanism of substrate recognition;Proceedings of the National Academy of Sciences;2023-08-21

2. Structural Optimization and Anticancer Activity of Polo-like Kinase 1 (Plk1) Polo-Box Domain (PBD) Inhibitors and Their Prodrugs;ACS Pharmacology & Translational Science;2023-02-20

3. Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer;Expert Opinion on Drug Discovery;2023-01-01

4. Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1;Journal of Medicinal Chemistry;2022-01-14

5. Recent Progress in Development of Polo-Like Kinase 1 Inhibitors: Efforts So Far;Pharmaceutical Sciences;2021-04-24